SUVRETTA CAPITAL MANAGEMENT, LLC 13D and 13G filings for Benitec Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-28 4:50 pm Purchase | 2025-03-26 | 13D | Benitec Biopharma Inc. BNTC | SUVRETTA CAPITAL MANAGEMENT, LLC | 15,623,659 49.900% | 1,293,722 (+9.03%) | Filing |
| 2024-11-18 4:36 pm Purchase | 2024-11-14 | 13D | Benitec Biopharma Inc. BNTC | SUVRETTA CAPITAL MANAGEMENT, LLC | 14,329,937 49.900% | 5,500,884 (+62.30%) | Filing |
| 2024-09-30 5:18 pm Purchase | 2024-09-26 | 13D | Benitec Biopharma Inc. BNTC | SUVRETTA CAPITAL MANAGEMENT, LLC | 8,829,053 49.900% | 7,128,203 (+419.10%) | Filing |
| 2024-04-29 4:08 pm Purchase | 2024-04-22 | 13D | Benitec Biopharma Inc. BNTC | SUVRETTA CAPITAL MANAGEMENT, LLC | 1,700,850 19.990% | 1,438,007 (+547.10%) | Filing |
| 2024-02-13 5:16 pm Purchase | 2023-12-31 | 13G | Benitec Biopharma Inc. BNTC | SUVRETTA CAPITAL MANAGEMENT, LLC | 262,843 9.990% | 262,843 (New Position) | Filing |